Lab testing. Source: Emyria
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Emyria Limited (EMD) announces the launch of its second proprietary, ultra-pure CBD formulation capsule EMD-RX7, said to contain a much higher bioavailable level than EMD-RX5 and on-market CBD oil Epidyolex
  • The more bioavailable EMD-RX7 may allow for a convenient, once to twice daily, oral dosing for indications requiring higher daily CBD exposures, saving the consumer cost
  • Phase 1 is expected to commence in the second half of 2022
  • Meanwhile, EMD-RX5 is expected to commence Phase 3 of clinical trials in May 2022
  • EMD shares are up 7.14 per cent, trading at 30 cents

Emyria (EMD) has launched its second proprietary, ultra-pure CBD formulation capsule EMD-RX7, said to contain a much higher bioavailable level than EMD-RX5 and on-market CBD oil Epidyolex.

In a preclinical pharmacokinetic study, EMD-RX7 was shown to have more than four times the bioavailability compared to an equivalent dose of Epidiolex, which means it will deliver more CBD into a patient’s bloodstream.

CBD is known to have poor bioavailability. For Epidyolex oil, only 6.49 per cent of consumed CBD enters the bloodstream at its fasted state, according to Emyria.

This means that the more bioavailable EMD-RX7 may allow for a convenient, once to twice daily, oral dosing for indications requiring higher daily CBD exposures.

This will in turn save cost for the consumer since more of the active ingredient can be absorbed without having to take more doses to reach the desired result.

“We know that most CBD available to patients has poor bioavailability… [which]
is why we have developed a range of convenient, ultra-pure CBD capsules with improved
bioavailability,” said Managing Director Michael Winlo.

“Now, with EMD-RX7, we have a convenient dose form that we believe can deliver higher CBD exposures more efficiently allowing us to target a range of prescription-only indications.

“In other words, [EMD-RX7 will] help the broad range of major unmet needs that affect the patients we treat every day at our clinical service subsidiary, Emerald Clinics.”

Dr Winlo has indicated that Emyria is now planning its Phase 1 trial for EMD-RX7 and “will continue to develop unique, proprietary, ultra-pure, cannabinoid-based medical treatments for other indications”.

Phase 1 is expected to commence in the second half of 2022, pending approval.

Meanwhile, EMD-RX5 is expected to commence Phase 3 of clinical trials in May 2022.

EMD shares are up 7.14 per cent, trading at 30 cents at 12:06 pm AEDT.

EMD by the numbers
More From The Market Herald
Beam Communications (ASX:BCC) - CEO, Michael Capocchi

" Beam Communications (ASX:BCC) raises $5m for ZOLEO

Communications equipment company Beam Communications (ASX:BCC) has successfully completed its share placement and raised $5 million.

" Beam Communications (ASX:BCC) sees Autobarn becomes latest retailer for ZOLEO

Beam Communications (ASX:BCC) signs a retail partnership agreement with Bapcor’s (BAP) Autobarn.
Beam Communications (ASX:BCC) - CEO, Michael Capocchi

" Beam Communications (ASX:BCC) signs partnership with Leisure-Tech for ZOLEO

Beam Communications (ASX:BCC) has signed a partnership with Leisure-Tec Australia for the deployment of its ZOLEO…

" Beam Communications (ASX:BCC) launches ZOLEO in UK & Europe

Beam Communications' (ASX:BCC) joint venture entity ZOLEO has officially launched its solution in the UK, Denmark,…